-
Anonymising Clinical Data for Secondary Use
Authors:
Irene Ferreira,
Chris Harbron,
Alex Hughes,
Tamsin Sargood,
Christoph Gerlinger
Abstract:
Secondary use of data already collected in clinical studies has become more and more popular in recent years, with the commitment of the pharmaceutical industry and many academic institutions in Europe and the US to provide access to their clinical trial data. Whilst this clearly provides societal benefit in hel** to progress medical research, this has to be balanced against protection of subjec…
▽ More
Secondary use of data already collected in clinical studies has become more and more popular in recent years, with the commitment of the pharmaceutical industry and many academic institutions in Europe and the US to provide access to their clinical trial data. Whilst this clearly provides societal benefit in hel** to progress medical research, this has to be balanced against protection of subjects' privacy. There are two main scenarios for sharing subject data: within Clinical Study Reports and Individual Patient Level Data, and these scenarios have different associated risks and generally require different approaches. In any data sharing scenario, there is a trade-off between data utility and the risk of subject re-identification, and achieving this balance is key. Quantitative metrics can guide the amount of de-identification required and new technologies may also start to provide alternative ways to achieve the risk-utility balance.
△ Less
Submitted 17 May, 2023;
originally announced July 2023.
-
The use of external controls: To what extent can it currently be recommended?
Authors:
Hans Ulrich Burger,
Christoph Gerlinger,
Chris Harbron,
Armin Koch,
Martin Posch,
Justine Rochon,
Anja Schiel
Abstract:
With more and better clinical data being captured outside of clinical studies and greater data sharing of clinical studies, external controls may become a more attractive alternative to randomized clinical trials. Both industry and regulators recognize that in situations where a randomized study cannot be performed, external controls can provide the needed contextualization to allow a better inter…
▽ More
With more and better clinical data being captured outside of clinical studies and greater data sharing of clinical studies, external controls may become a more attractive alternative to randomized clinical trials. Both industry and regulators recognize that in situations where a randomized study cannot be performed, external controls can provide the needed contextualization to allow a better interpretation of studies without a randomized control. It is also agreed that external controls will not fully replace randomized clinical trials as the gold standard for formal proof of efficacy in drug development and the yardstick of clinical research. However, it remains unclear in which situations conclusions about efficacy and a positive benefit/risk can reliably be based on the use of an external control. This paper will provide an overview on types of external control, their applications and the different sources of bias their use may incur, and discuss potential mitigation steps. It will also give recommendations on how the use of external controls can be justified.
△ Less
Submitted 16 September, 2022;
originally announced September 2022.
-
Patient-reported outcomes in the context of the benefit assessment in Germany
Authors:
Sarah Böhme,
Christoph Gerlinger,
Susanne Huschens,
Annett Kucka,
Niclas Kürschner,
Friedhelm Leverkus,
Michael Schlichting,
Waldemar Siemens,
Kati Sternberg,
Li** Hofmann-Xu
Abstract:
Since the 2011 Act on the Reform of the Market for Medicinal Products, benefit dossiers are submitted by pharmaceutical companies to facilitate the Health Technology Assessment (HTA) appraisals in Germany. The Institute for Quality and Efficiency in Health Care conducts the added benefit assessment following their General Methods Paper, which was updated November 5, 2020. This White Paper is dedic…
▽ More
Since the 2011 Act on the Reform of the Market for Medicinal Products, benefit dossiers are submitted by pharmaceutical companies to facilitate the Health Technology Assessment (HTA) appraisals in Germany. The Institute for Quality and Efficiency in Health Care conducts the added benefit assessment following their General Methods Paper, which was updated November 5, 2020. This White Paper is dedicated to patient-reported outcomes (PRO) to highlight their importance for the added benefit assessment. We focus on methodological aspects but consider also other relevant requirements and challenges, which are demanded by G-BA and IQWiG. The following topics will be presented and discussed: 1. Role of PRO in HTA decision making exemplary to benefit assessment in Germany 2. Guidances of PRO evaluations 3. PRO Estimand framework 4. Perception and requirements for PRO within the German benefit assessment 5. Validity of instrument 6. Response thresholds for assessing clinical relevance of PRO 7. PRO endpoints / outcome measures / operationalization 8. Missing PRO data 9. PRO after treatment discontinuation This White Paper aims to provide deeper insights about new requirements concerning PRO evaluations for HTA decision making in Germany, highlight points to consider that should inform global development in terms of study planning and frame the requirements also in the context of global recommendations and guidelines. We also aim to enhance the understanding of the complexity when preparing the benefit dossier and promote further scientific discussions where appropriate.
△ Less
Submitted 23 July, 2021; v1 submitted 7 July, 2021;
originally announced July 2021.
-
Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?
Authors:
Cornelia Ursula Kunz,
Silke Jörgens,
Frank Bretz,
Nigel Stallard,
Kelly Van Lancker,
Dong Xi,
Sarah Zohar,
Christoph Gerlinger,
Tim Friede
Abstract:
Very recently the new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified and the coronavirus disease 2019 (COVID-19) declared a pandemic by the World Health Organization. The pandemic has a number of consequences for the ongoing clinical trials in non-COVID-19 conditions. Motivated by four currently ongoing clinical trials in a variety of disease areas we illustra…
▽ More
Very recently the new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified and the coronavirus disease 2019 (COVID-19) declared a pandemic by the World Health Organization. The pandemic has a number of consequences for the ongoing clinical trials in non-COVID-19 conditions. Motivated by four currently ongoing clinical trials in a variety of disease areas we illustrate the challenges faced by the pandemic and sketch out possible solutions including adaptive designs. Guidance is provided on (i) where blinded adaptations can help; (ii) how to achieve type I error rate control, if required; (iii) how to deal with potential treatment effect heterogeneity; (iv) how to utilize early readouts; and (v) how to utilize Bayesian techniques. In more detail approaches to resizing a trial affected by the pandemic are developed including considerations to stop a trial early, the use of group-sequential designs or sample size adjustment. All methods considered are implemented in a freely available R shiny app. Furthermore, regulatory and operational issues including the role of data monitoring committees are discussed.
△ Less
Submitted 28 May, 2020;
originally announced May 2020.
